Change of Registered Office

Summary by AI BETAClose X

MedPal AI plc has announced an immediate change to its registered office, relocating to Floor 8, 71 Queen Victoria Street, London EC4V 4AY. This administrative update does not involve any financial figures or operational changes that would directly impact the company's stock share price at this time. The company continues its operations as an AI-powered digital health provider, integrating data from various health apps and wearables, and operating an automated pharmacy distribution centre.

Disclaimer*

Medpal AI PLC
01 May 2026
 

1 May 2026

MedPal AI plc

("MedPal AI" or the "Company")

Change of Registered Office

 

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, announces that its registered office has changed with immediate effect to Floor 8, 71 Queen Victoria Street, London EC4V 4AY.

 

The Directors of the Company are responsible for the release of this announcement.

 

For further information visit www.medpalai.com or contact the following:

Enquiries:

MedPal AI plc

Mr Drummond, Chief Executive Officer

 

 

Via Square1 Consulting

Cairn Financial Advisers LLP         

(Nominated Adviser)

Louise O'Driscoll/Jo Turner

 

+44 (0) 20 7213 0880

Oak Securities (a trading name of Merlin Partners LLP)

(Joint Broker)

Tim Dainton/Calvin Man

 

+44 (0) 20 3973 3678

Clear Capital Markets Limited

(Joint Broker)

Bob Roberts

 

+44 (0) 20 3869 6080

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings